Acute anterior STEMI. ST elevation (STEMI) myocardial infarction of anterior wall
Conditions
Interventions
Intervention 1: A total of 966 tablets (the total number of tablets required for distribution among the intervention group) of Colchicine 1 mg manufactured by Sinapishgam Daru Novin Company will be pr
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients with acute anterior STEMI will be included in the study.
Exclusion criteria
Exclusion criteria: stroke in the last 3 months Type 2 Index MI CABG in the last 3 years or decision to undergo surgery History of non-skin malignancies in the last 3 years Inflammatory bowel disease (IBD) Chronic diarrhea Neuromuscular diseases with a CK level greater than 3 times the maximum normal (except for diseases that have led to muscle infarction) Chronic hematological diseases Current treatment with corticosteroids or other anti-inflammatory drugs Known sensitivity to colchicine or current chronic treatment with Colchicine Severe kidney failure (Cr>2 upper limit of the normal range) Severe liver failure History of alcohol or drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricle function. Timepoint: The effect of colchicine on left ventricular function at the beginning of the study (before the start of the intervention) and 4 to 6 weeks after administration. Method of measurement: Echocardiography machine. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNiloofar Salari
Tabriz University of Medical Sciences
Outcome results
None listed